

1 **Title:** Disease-modifying immune-modulatory effects of the N-163 strain of Aureobasidium
2 pullulans-produced 1,3-1,6 Beta glucans in young boys with Duchenne muscular dystrophy:
3 Results of an open-label, prospective, randomized, comparative clinical study

4 **Running Title:** N-163 beta glucan as disease modifying agent in DMD

5 **Authors:**

6 Kadalraja Raghavan^{1,2,3} (drkraghavan@nichimail.jp)

7 Vidyasagar Devaprasad Dedeepiya⁴ (dedeepiya_76@yahoo.co.in)

8 Subramaniam Srinivasan⁴ (masala76@gmail.com)

9 Subramanian Pushkala⁵ (pushkala66m@gmail.com)

10 Sudhakar Subramanian⁶ (drsudhakar77@gmail.com)

11 Nobunao Ikewaki^{7,8} (nikewaki@phoenix.ac.jp)

12 Masaru Iwasaki⁹ (miwasaki@yamanashi.ac.jp)

13 Rajappa Senthilkumar¹⁰ (rsk@nichimail.jp)

14 Senthilkumar Preethy¹⁰ (drspp@nichimail.jp)

15 Samuel JK Abraham^{4,9,11} (drsam@nichimail.jp)

16 **Affiliations:**

17 1. Dept of Paediatric Neurology, Jesuit Antonyraj memorial Inter-disciplinary Centre for
18 Advanced Rehabilitation and Education (JAICARE), Madurai, India

19 2. Department of Paediatric Neurology, Kenmax Medical Service Private Limited,
20 Madurai, India.

21 3. Department of Paediatric Neurology, Sarvee Integra Private Limited, Chennai, India.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 22 4. Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative
23 Medicine (NCRM), Chennai, India.
- 24 5. Department of Immunology, The Tamil Nadu Dr. M.G.R. Medical University,
25 Chennai, 600032, India.
- 26 6. Department of Anesthesia and Pain service, Toronto Western Hospital, 399 Bathurst
27 street Toronto, Ontario, Canada.
- 28 7. Dept. of Medical Life Science, Kyushu University of Health and Welfare, Japan
- 29 8. Institute of Immunology, Junsei Educational Institute, Nobeoka, Miyazaki, Japan
- 30 9. Centre for Advancing Clinical Research (CACR), University of Yamanashi - School of
31 Medicine, Chuo, Japan.
- 32 10. Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine
33 (NCRM), Chennai, India.
- 34 11. Antony- Xavier Interdisciplinary Scholastics (AXIS), GN Corporation Co. Ltd., Kofu,
35 Japan

36 **Corresponding author information:**

37 Dr. Samuel JK Abraham,

38 II Department of Surgery & CACR,

39 University of Yamanashi, Faculty of Medicine

40 Address for correspondence: 3-8, Wakamatsu, Kofu, 400-0866, Yamanashi, Japan

41 Email id- drsam@nichimail.jp; Alternate email id: drsp@nichimail.jp

42 Fax: +81-55-235-7569

43

44

45 **Acknowledgements:**

The authors thank

- 46 1. The Government of Japan and the Prefectural Government of Yamanashi for a special
47 loan and M/s Yamanashi Chuo Bank for processing the transactions.
- 48 2. Ms. Sunitha, Mr. Vincent, Mr. Shivakumar (Physiotherapist), Dr. Madhankumar and
49 the staff of Kenmax & Sarvee Integra, for their assistance during the clinical study and
50 data collection of the manuscript.
- 51 3. Fr. Francis Xavier, Fr. Vargheesh Antony, Fr. Marianathan and Mr Jeyachandran of
52 JAICARE for their support during the clinical study.
- 53 4. Mr. Takashi Onaka, Mr. Yasunori Ikeue, Mr. Mitsuru Nagataki (Sophy Inc, Kochi,
54 Japan), for necessary technical clarifications.
- 55 5. Mr. Yoshio Morozumi and Ms. Yoshiko Amikura of GN Corporation, Japan for their
liaison assistance with the conduct of the study.
- 56 6. Loyola-ICAM College of Engineering and Technology (LICET) for their support to
our research work.

Conflicts of interest/Competing interests: Author Samuel Abraham is a shareholder in GN Corporation, Japan which in turn is a shareholder in the manufacturing company of the Beta Glucans described in the study.

57 **Ethics Approval:**

58 The study was registered in Clinical trials registry of India, CTRI/2021/05/033346. Registered
59 on 5th May, 2021. The study was approved by the Institutional Ethics Committee (IEC) of
60 Saravana Multispeciality Hospital, India on 12th April, 2021.

61

62 **Funding:**

63 No external funding was received for the study

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82 **Abstract**

83 **Background:** Duchenne muscular dystrophy (DMD) is an inherited neuromuscular disorder
84 causing progressive muscle weakness and premature death. Steroids remain the mainstream
85 approach for supportive care but have side effects; other targeted therapies and gene therapies
86 are also being developed. As there is limited evidence on the use of disease-modifying
87 nutritional supplement adjuncts in DMD, this pilot trial is to evaluate the effects of
88 supplementation of *Aureobasidium pullulans*-derived 1,3-1,-6 beta glucan from the N-163
89 strain in young patients with DMD.

90 **Methods:**

91 Twenty-seven patients with Duchenne muscular dystrophy (DMD)—nine in the control arm
92 (undergoing conventional therapies)—participated. The patients were divided into groups:
93 those not administered steroids (Steroid -ve) (n = 5), those administered steroids (Steroid +ve)
94 (n = 4), and 18 in the treatment arm (N-163 beta glucan supplement along with conventional
95 therapies; N-163 Steroid –ve and N-163 Steroid +ve); they participated in the study for 45 days.
96 Assessments of muscle function, disease status, and levels of IL-6, IL-13, TGF- β , creatinine
97 kinase (CK), titin, TNF- α , haptoglobin, and dystrophin in the blood and myoglobin in the urine
98 were performed at baseline and at the end of the study.

99 **Results:**

100 IL-6 showed a significant decrease in the N-163 Steroid -ve group, from a baseline value of
101 7.2 ± 1.2 pg/ml to 2.7 ± 0.03 pg/ml. IL-13 decreased in both treatment groups—from $157.76 \pm$
102 148.68 pg/ml to 114.08 ± 81.5 pg/ml (N-163 Steroid -ve) and from 289.56 ± 232.88 pg/ml to
103 255.56 ± 214.13 pg/ml (N-163 Steroid +ve). TGF- β levels showed a significant decrease in the
104 N-163 Steroid –ve group, from a baseline value of 3302 ± 1895 ng/ml to 1325.66 ± 517 ng/ml
105 post intervention. Dystrophin levels increased by up to 32% in both Steroid +ve and -ve groups.

106 Medical research council (MRC) grading showed muscle strength improvement in 12 out of
107 18 patients (67%) in the treatment group and four out of nine (44%) subjects in the control
108 group.

109 **Conclusion:**

110 Supplementation with the N-163 beta glucan food supplement produced disease-modifying
111 beneficial effects: a significant decrease in inflammation and fibrosis markers, increase in
112 dystrophin and improvement in muscle strength in DMD subjects over 45 days, thus making
113 this a potential adjunct treatment for DMD after validation. A longer duration of follow-up and
114 further research on the mechanism of action and commonalities with other diseases provoked
115 by hyperactive inflammation and/or fibrosis may pave the way for their extended applications
116 in other dystrophinopathies and neuroinflammatory diseases.

117 **Trial registration:** Clinical trials registry of India, CTRI/2021/05/033346. Registered on 5
118 May, 2021.

119

120

121

122

123

124

125

126

127

128 **Introduction:**

129 Duchenne muscular dystrophy (DMD) is a devastating X-linked neuromuscular disorder
130 causing severe and progressive weakness of skeletal muscles, leading to loss of ambulation
131 along with concomitant impairment of cardiac and respiratory muscles and early mortality.
132 Mutations in the dystrophin gene, which cause total loss of the dystrophin protein [2], remain
133 the major underlying mechanism. Loss of dystrophin leads to damage of the myofibres' plasma
134 membranes and distorts the structural stability of the plasma, leading to weakness in the
135 myofibres. The weakened myofibres cannot withstand the contraction and relaxation cycles
136 occurring during muscle function. The damage to the membrane releases the cytoplasmic
137 contents, triggering the immune system and causing further muscle fibre damage, weakness
138 and ultimately death [3]. A chronic proinflammatory state ensues, with neutrophil infiltration
139 and macrophages' phagocytosis of the degenerated tissue [3], preventing repair of the muscle
140 damage, which otherwise occurs in a highly orchestrated manner for faster repair in other
141 physiological conditions. The muscle is relatively immunologically privileged, with a low
142 capacity to generate localized immune responses and thus having low rates of abscess and
143 granuloma formation [3]. Therefore, it becomes essential to modulate the inflammation and
144 immunity to resolve the chronic inflammatory state in therapeutic approaches to DMD. Steroid
145 therapy is the most commonly employed immuno-modulatory treatment approach. However,
146 side effects include weight gain, weak bones, high blood pressure and behaviour changes in
147 addition to muscle weakness and atrophy in the long term [4,5]. Thus, there arises the need to
148 develop strategies that will assist in immunomodulation with lesser side effects. Nutritional
149 supplements are a potential option. Beside beta glucans yielding locomotor improvement in
150 zebrafish models of DMD [6], a 1-3,1-6 beta glucan from the N-163 strain of the black yeast
151 *Aureobasidium pullulans* has been reported to mitigate inflammation, evident by decreases in
152 anti-inflammatory markers such as CD11b, serum ferritin, galectin-3 and fibrinogen. It also

153 produces beneficial immuno-modulation via a decrease in the neutrophil-to-lymphocyte ratio
154 (NLR) and an increase in the lymphocyte-to-CRP ratio (LCR) and leukocyte-to-CRP ratio
155 (LeCR) in human healthy volunteers [7]. Mitigation of lipotoxicity-associated inflammatory
156 cascades in a mouse study has also been reported [8]. Another study done in an animal model
157 of non-alcoholic steatohepatitis (NASH) showed a decrease in liver inflammation and
158 accumulation of F4/80+ cells (macrophages associated with inflammation) [9] in the liver. The
159 present pilot study is to evaluate the immunomodulatory efficacy of the N-163 strain of A.
160 pullulans-produced beta 1-3,1-,6 glucan in comparison with a conventional therapeutic
161 regimen in patients with DMD.

162 **Methods:**

163 This trial was an investigator-initiated, single-centre, randomized, open-label, prospective,
164 comparative, two-arm clinical study of patients with DMD. The study was conducted over 45
165 days. The two treatment arms included

166 ***Treatment arm I***, control arm: Conventional treatment regimen comprising standard routine
167 physiotherapy for joint mobility along with medications, viz., T. calcium and vit. D 1000 with
168 or without T. deflocort (steroid) 6mg to 24 mg.

169 ***Treatment arm II***, intervention: One sachet of N-163 beta glucan (16 mg gel) once daily along
170 with conventional treatment.

171 ***Inclusion criteria:*** Male subjects with molecular diagnosis of DMD aged 6-18 years who were
172 willing to participate in the study with written informed consent.

173 ***Exclusion criteria:*** Patients with a previous (within the past 1 month) or concomitant
174 participation in any other therapeutic trial; a known or suspected malignancy; any other chronic
175 disease or clinically relevant limitation of renal, liver or heart function according to the
176 discretion of the investigator.

177 ***Investigations:***

178 The following tests were carried out after written consent was obtained from the study
179 subjects.

180 ***At baseline and at the end of the study (after 45 days):***

- 181 • Background survey: gender, date of birth, age, habits, current medical history,
182 medication, treatment, allergies (to drugs and food), regular use of food for specified
183 health uses, functional foods, health foods, intake of foods rich in β -glucan foods
184 containing beta-glucan and intake of immunity-boosting foods
- 185 • Medical history and physical measurements: height, weight, BMI, temperature
- 186 • Physiological examination: systolic blood pressure, diastolic blood pressure, pulse rate
- 187 • ECG
- 188 • Muscle strength test using MRC grading [10]
- 189 • Six-minute walk test (6MWT) [11]
- 190 • North Star Ambulatory Assessment (NSAA) [12]
- 191 • Blood sampling and investigations for the levels of IL-6, IL-13, TGF- β , creatinine
192 kinase (CK), titin, haptoglobin, TNF- α , dystrophin, cystatin in the blood and myoglobin
193 in the urine
- 194 • Subjects were contacted every week for drug compliance and recording of adverse
195 effects, if any

196 ***Study subjects = 28***

197 The study was designed as an exploratory study, so there were two intervention conditions: one
198 control and one test group. As the minimum number of participants required for statistical
199 comparisons within and between intervention conditions is four per intervention condition, a

200 total of 28 target study participants (10 in treatment arm I [control] group and 18 in treatment
201 arm II [N-163]) were used.

202 *Selection of study subjects*

203 Study investigators and other investigators included study subjects who had consented to
204 participate in the study, met the selection criteria and not the exclusion criteria, and who were
205 judged to have no problem participating in the study.

206 *Allocation of study subjects*

207 The person in charge of the allocation, as specified in the study protocol, allocated the study
208 subjects to the two groups by simple randomization.

209 *Primary outcome:*

210 Observation of changes in the levels of IL-6 and myoglobin urea from the baseline.

211 *Secondary outcome:*

- 212 • Observation of changes in the levels of IL-6, IL-13, TGF- β , CK, titin, dystrophin,
213 haptoglobin, cystatin C, and TNF- α in the serum and urine myoglobin levels measured
214 by ELISA.
- 215 • Monitoring for adverse effects

216 *Statistical analysis:*

217 All data were analysed using Excel statistics package analysis software (Microsoft Office
218 Excel®); Student's t-tests and ANOVA were used. When there was a significant main effect,
219 post hoc pairwise comparisons were performed, and p-values < 0.05 were considered
220 significant.

221

222 **Results:**

223 Twenty-eight patients were screened and 27 were randomized to control (n = 9) and treatment
224 (n = 18). One patient was disqualified due to misrepresentation of diagnosis. The CONSORT
225 flow diagram of the trial is shown in Figure 1.

226 Demographics are shown in Table 1. The mean \pm SD age for the total study population was
227 11.18 ± 3.86 years (range 5-19 years) and was similar across the groups. The mean \pm SD
228 body weight was 35.59 ± 15.5 kgs (range = 10 to 65 kgs).

229 The distribution of patients was as follows:

230 Group I: Control group (n = 9);

231 A. Steroids not administered (n = 5) (Steroid -ve)

232 B. Steroids administered (n = 4) (Steroid +ve)

233 Group II: Treatment (N-163) group (n = 18);

234 A. Steroids not administered (n = 9) (Steroid -ve)

235 C. Steroids administered (n = 9) (Steroid +ve)

236 No adverse events were reported. No clinically significant changes from baseline data were
237 observed on physical examination or in vital signs—temperature, blood pressure, oxygen
238 saturation, pulse rate or ECG (data not shown).

239 ***Biomarker levels:***

240 Levels are expressed as mean \pm SD. IL-6 showed the highest decrease in the N-163 Steroid -
241 ve group, from a baseline value of 7.2 ± 1.2 pg/ml to 2.7 ± 0.03 ng/ ml post intervention, but
242 the difference was not significant (p-value = 0.16) (Figure 2).

243 IL-13 increased in both control groups—from 300.4 ± 114.5 pg/ml at baseline to $550.732 \pm$
244 107.95 pg/ml post-intervention in the Steroid -ve group and from 142 ± 112.82 pg/ml at
245 baseline to 263.5 ± 99.38 pg/ml post-intervention in the Steroid +ve group. It decreased in
246 both the treatment groups—from 157.76 ± 148.68 pg/ml at baseline to 114.08 ± 81.5 pg/ml
247 post-intervention and from 289.56 ± 232.88 pg/ml at baseline to 255.56 ± 214.13 pg/ml post-
248 intervention. The difference was statistically significant (p-value = 0.004) (Figure 3).

249 TGF- β levels showed a significant decrease in the N-163 Steroid -ve group, from a baseline
250 value of 3302 ± 1895 ng/ml to 1325.66 ± 517 ng/ml post intervention, which was
251 significantly lower than all the other groups (p-value = 0.0001) (Figure 4).

252 Dystrophin levels showed a significant increase in the N-163 Steroid -ve group, from a
253 baseline value of 3.01 ± 1.58 ng/ml to 4.01 ± 1.44 ng/ml post intervention, and the N-163
254 Steroid +ve group went from a baseline value of 3.15 ± 2.43 ng/ml to 3.78 ± 2.17 ng/ml post
255 intervention, which was significantly higher than the control groups (p-value = 0.0009)
256 (Figure 2). The N-163 Steroid -ve group showed higher dystrophin expression than the N-163
257 Steroid +ve group, but the difference was not significant (p-value = 0.11). The percentage
258 increase in dystrophin levels in the treatment group was up to 32.8%.

259 Haptoglobin did not show much difference pre or post intervention in the treatment groups,
260 but it was marginally increased in the control group (Figure 6A). CK increased in the
261 treatment groups (Figure 6B). Urine myoglobin increased in the N-163 Steroid +ve group but
262 decreased in all the other groups (Figure 6C).

263 Titin and cystatin C decreased in the N-163 Steroid +ve group and the control Steroid +ve
264 group, but the difference was not significant (Figure 7A.B). TNF- α decreased in all the
265 groups except the N-163 Steroid -ve group.

266 The 6MWT and NSAA did not show any significant differences between the groups (Figure
267 8 A, B). The MRC grading showed improvement in 12 out of 18 patients (67%) in the
268 treatment group and only four out of nine (44%) subjects in the control group (Table 2).

269 **Discussion:**

270 Current interventions for DMD, such as corticosteroids and rehabilitative care, help to prolong
271 survival up to the third or the fourth decade of life. Corticosteroids remain the mainstream
272 supportive approach to slow inflammation and the associated decline in muscle strength and
273 function [4]. However, steroids have their own adverse effects, and their prescription is based
274 on risk versus benefit to that specific patient and tolerance to the medication. Exon-skipping
275 gene therapy and cell-based strategies to replace the mutant DMD gene are in development,
276 but the desired outcome has not yet been achieved. In the meantime, nutraceuticals can be
277 considered potential strategies for immune modulation and alleviating inflammation, as they
278 are safer with lesser adverse effects [4]. Improvement of the locomotor performances and
279 mitochondrial respiration by 1,3-1,6 beta-glucans in zebra fish model of muscular dystrophy
280 [6] has already been reported.

281 In the current study, we focussed on a 1-3,1-6 beta glucan from the N-163 strain of the black
282 yeast *A. pullulans* that has been reported to mitigate inflammation, evidenced by a decrease in
283 anti-inflammatory markers and production of beneficial immuno-modulation [6-8]. The safety
284 profile of N-163 beta glucan has been confirmed by the results.

285 **Anti-inflammatory and anti-fibrotic outcomes:** Circulating IL-6 is chronically elevated in
286 individuals with DMD [13], which has been reported to contribute to DMD-associated
287 cognitive dysfunction. IL-6 blockades have been advocated as a therapeutic approach for
288 DMD [14]. In the present study, IL-6 showed highest decrease in the N-163 Steroid -ve group
289 (Figure 2). While IL-6 is an acute inflammatory biomarker [14], IL-13 is a pro-fibrotic

290 biomarker [15] and was significantly decreased (Figure 3). Together with the TGF- β pathway,
291 it is a major proinflammatory and pro-fibrotic cytokine responsible for the chronic
292 inflammatory response leading to replacement of the muscle by scar tissue or fibrosis, resulting
293 in muscle weakness and loss of muscle function [16]. TGF- β levels also showed a significant
294 decrease in the N-163 Steroid -ve group (Figure 4). Dystrophin restoration of 20% expression
295 [17,18] is considered the point of efficacy for a DMD therapy [19] and was found to increase
296 by 32.8% in both the treatment groups (Figure 5) of the present study from baseline. This
297 establishes N-163 beta glucan as an efficient agent for DMD. This dystrophin increase could
298 be attributed to the immune modulation proven through control of anti-inflammatory and anti-
299 fibrotic markers (IL-6, IL-13 and TGF- β).

300 **Other biochemical markers of relevance:** While haptoglobin and urine myoglobin did not
301 show significant differences, the increase in urine myoglobin in the N-163 Steroid +ve group
302 deserves more analysis concerning the underlying mechanism. Greater activity among steroid-
303 treated individuals may place their dystrophin-deficient muscles under greater mechanical
304 stress, predisposing them to further muscle fibre damage and consequent myoglobinuria [20].
305 While titin and cystatin C decreased in the N-163 steroid +ve group and in the control Steroid
306 +ve group, there was an increase in CK, which is paradoxical, as reports suggest that titin
307 concentration correlates significantly with serum CK concentration [21].

308 **Muscle strength evaluation:** There were three evaluations to assess muscle strength and tone,
309 done in a blinded manner by the same physiotherapist at baseline and post intervention. Though
310 the 6MWT and NSAA did not show any significant differences between the groups, MRC
311 grading showed improvement of muscle strength in 67% of the subjects in the treatment group
312 compared to 44% subjects in the control group, which is significant. The limitation of this being
313 a 45-day study is relevant to the muscle-strength and functional evaluations, mandating the
314 need for a longer study and follow-up duration. However, though small, the improvement in

315 MRC grading at 45 days could be again attributed to the immune modulation effects of this
316 disease-modifying supplement. The study shows proof of concept that DMD could be tackled
317 by the N-163 beta glucan from three aspects: decrease in inflammation shown by decreased
318 IL-6 and TNF- α , decrease in fibrosis evident by decreased TGF- β and IL-13 and, more
319 importantly, restoration of dystrophin evident from a 32.8% increase in dystrophin levels.
320 These effects hold regardless of the use or non-use of steroids, which is important, as this
321 safety-proven food supplement can help DMD patients regardless of steroid status.

322 Chronic inflammation being common to pathogenesis of all muscular dystrophies,
323 immunomodulatory treatment may benefit patients with diverse types of muscular dystrophy
324 [22]. Further, modulating the inflammatory response and inducing immunological tolerance to
325 de novo dystrophin expression is critical to the success of dystrophin-replacement therapies
326 [23]. The need to evaluate the muscles involved in respiratory function and myocardium should
327 be mentioned here, as they are the cause of mortality in most of the DMD patients [1]. Though
328 other dystrophinopathies, such as limb girdle muscular dystrophy (LGMD), do not involve
329 respiratory or cardiac muscles, inflammatory overactivity is the common pathophysiology
330 among types of muscular dystrophy [22]. Once proven efficacious for DMD, extending the
331 beneficial application of the N-163 beta glucans to other dystrophinopathies such as LGMD
332 can be considered.

333
334 DMD is a rare genetic disease with a maximum life expectancy of up to fourth decade, with
335 the majority of victims dying in their late twenties to thirties. The average lifespan at birth,
336 which was 20+ years for those born in or before 1970, has gradually increased by 10~15 years
337 for those born and diagnosed with DMD in the 1980s and 1990s. This increase is attributed to
338 better or early ventilatory assistance, steroid usage and cardiac care [24,25], which are only
339 supportive interventions. With the gene therapies approved recently, there is a hope of

340 additional progress and increase in lifespan [26]. Though these gene therapies (such as exon
341 skipping) address the root cause by splicing out selected exons from the pre-mRNA at or next
342 to the mutation site, generating a translatable transcript from the mutant dystrophin gene
343 leading to dystrophin expression [26, 27], they are still marred by challenges such as delivery
344 of gene-editing components throughout the musculature and mitigation of possible immune
345 responses [28]. The current need, therefore, is to modulate the immune system and control the
346 inflammation and ensuing fibrosis to delay the progression of the disease. The earlier usage of
347 steroids in a regular manner was later changed to intermittent usage [29] with regimens varying
348 between institutes; now, newer steroids with lesser adverse effects are in various stages of
349 progress towards clinical applications [30]. In this background, the safety of this N-163-
350 produced beta glucan food supplement without adverse reactions is to be considered an
351 indispensable value addition. Targeting the inflammation component (the criteria for selecting
352 this supplement for this study) having yielded beneficial outcomes, additional studies on this
353 characteristic could be of value to possibly extending their application for other
354 neuroinflammatory diseases, such as multiple sclerosis. At this point, it is essential to mention
355 the gut microbiome for two reasons; one being the association of the microbiome with the
356 severity of neuroinflammatory conditions such as multiple sclerosis [31], and another being
357 the fact that beta glucans have been reported to yield beneficial reconstitution of the gut
358 microbiome in earlier studies [32] in children with autism spectrum disorder, a
359 neurodevelopmental disease. For both multiple sclerosis and DMD, steroids to suppress
360 inflammation are common, but associated implications for gut microbiota in DMD have not
361 been reported often and are worthy of future study.

362 The limitations of the study include uneven distribution of subjects and short follow-up (only
363 45 days); improvements in muscle function over the course of the study showed variability that
364 may have been due to the level of sensitivity to change of functional assessments during the

365 disease progression in the age group. Among the 27 subjects, two-thirds were ambulatory and
366 the remaining non-ambulatory; the evaluation criteria differences must be kept in mind, which
367 may show equivalent quantification among all DMD patients at different stages of disease
368 severity when non-invasive myograms to measure the individual muscles accurately could be
369 undertaken. Further, consumption of steroids vs those who did not consume them or those who
370 had stopped steroids after an initial duration of consumption, as well as regimen variation, are
371 to be considered while interpreting the outcomes. All these aspects mandate the need for larger
372 randomized clinical trials of longer duration to validate this supplement as a treatment.

373 **Conclusion:**

374 N-163 beta glucan with and without steroids helped decrease IL-6, TGF- β and IL-13 and
375 increase dystrophin levels along with improvement of muscle strength in subjects with DMD
376 in this clinical study. Thus, N-163 beta glucan is a safe and effective potential therapeutic
377 disease-modifying adjunct for patients with DMD. While the benefits documented may help
378 slow the rate of progression of this devastating disease, confirmation by longer and larger
379 studies will help establish this agent for routine clinical application as a disease-modifying
380 agent with the potential to help prolong the lifespan of DMD patients. After such validation,
381 extending its application to other dystrophinopathies such as LGMD could be considered, and
382 further in-depth research on gut microbiomes and their implications in neuroinflammatory
383 diseases are likely to shed light on the mechanism of action, leading to additional beneficial
384 applications.

385

386

387

388

389 **References:**

- 390 1. Theadom A, Rodrigues M, Roxburgh R, Balalla S, Higgins C, Bhattacharjee R, Jones
391 K, Krishnamurthi R, Feigin V. Prevalence of muscular dystrophies: a systematic
392 literature review. *Neuroepidemiology*. 2014;43(3-4):259-68.
- 393 2. Nagy S, Hafner P, Schmidt S, Rubino-Nacht D, Schädelin S, Bieri O, Fischer D.
394 Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a
395 multicenter, randomized, placebo-controlled, double-blind phase 3 trial. *Trials*.
396 2019;20(1):637.
- 397 3. Rosenberg AS, Puig M, Nagaraju K, Hoffman EP, Villalta SA, Rao VA, Wakefield
398 LM, Woodcock J. Immune-mediated pathology in Duchenne muscular dystrophy. *Sci*
399 *Transl Med*. 2015;7(299):299rv4.
- 400 4. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne
401 muscular dystrophy. *Cochrane Database Syst Rev*. 2004;(2):CD003725.
- 402 5. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Spotlight on
403 Research: Optimizing Steroid Treatment for Duchenne Muscular Dystrophy
404 [https://www.niams.nih.gov/newsroom/spotlight-on-research/optimizing-steroid-](https://www.niams.nih.gov/newsroom/spotlight-on-research/optimizing-steroid-treatment-duchenne-muscular-dystrophy)
405 [treatment-duchenne-muscular-dystrophy](https://www.niams.nih.gov/newsroom/spotlight-on-research/optimizing-steroid-treatment-duchenne-muscular-dystrophy) (Accessed: December 13, 2021).
- 406 6. Licitra R, Marchese M, Brogi L, Fronte B, Pitto L, Santorelli FM. Nutraceutical
407 Screening in a Zebrafish Model of Muscular Dystrophy: Gingerol as a Possible Food
408 Aid. *Nutrients*. 2021;13(3):998.
- 409 7. Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M, Dedeepiya VD, Senthilkumar R,
410 Preethy S, Abraham SJK. Immune and metabolic beneficial effects of Beta 1,3-1,6
411 glucans produced by two novel strains of *Aureobasidium pullulans* in healthy middle-
412 aged Japanese men: An exploratory study. medRxiv 2021.08.05.21261640; doi:
413 10.1101/2021.08.05.21261640

- 414 8. Ikewaki N, Onaka T, Ikeue Y, Nagataki M, Kurosawa G, Dedeepiya VD, Rajmohan
415 M, Vaddi S, Senthilkumar R, Preethy S, Abraham SJK. Beneficial effects of the AFO-
416 202 and N-163 strains of *Aureobasidium pullulans* produced 1,3-1,6 beta glucans on
417 non-esterified fatty acid levels in obese diabetic KKAY mice: A comparative
418 study. *bioRxiv* 2021.07.22.453362; doi: 10.1101/2021.07.22.453362
- 419 9. Ikewaki N, Kurosawa G, Iwasaki M, Preethy S, Dedeepiya VD, Vaddi S, Senthilkumar
420 R, Levy GA, Abraham SJK. Hepatoprotective effects of *Aureobasidium pullulans*
421 derived Beta 1,3-1,6 biological response modifier glucans in a STAM- animal model
422 of non-alcoholic steatohepatitis. *bioRxiv* 2021.07.08.451700; doi:
423 10.1101/2021.07.08.451700
- 424 10. MRC Muscle Scale. [https://mrc.ukri.org/research/facilities-and-resources-for-](https://mrc.ukri.org/research/facilities-and-resources-for-researchers/mrc-scales/mrc-muscle-scale/)
425 [researchers/mrc-scales/mrc-muscle-scale/](https://mrc.ukri.org/research/facilities-and-resources-for-researchers/mrc-scales/mrc-muscle-scale/) (Accessed: December 13, 2021).
- 426 11. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, Atkinson
427 L, Reha A, Hirawat S, Miller LL. The 6-minute walk test as a new outcome measure in
428 Duchenne muscular dystrophy. *Muscle Nerve*. 2010;41(4):500-10
- 429 12. Scott E, Eagle M, Mayhew A, Freeman J, Main M, Sheehan J, Manzur A, Muntoni F;
430 North Star Clinical Network for Paediatric Neuromuscular Disease. Development of a
431 functional assessment scale for ambulatory boys with Duchenne muscular dystrophy.
432 *Physiother Res Int*. 2012;17(2):101-9. doi: 10.1002/pri.520.
- 433 13. Stephenson KA, Rae MG, O'Malley D. Interleukin-6: A neuro-active cytokine
434 contributing to cognitive impairment in Duchenne muscular dystrophy? *Cytokine*.
435 2020;133:155134.
- 436 14. Mammen AL, Sartorelli V. IL-6 Blockade as a Therapeutic Approach for Duchenne
437 Muscular Dystrophy. *EBioMedicine*. 2015;2(4):274-5.

- 438 15. Mann CJ, Perdiguero E, Kharraz Y, Aguilar S, Pessina P, Serrano AL, Muñoz-Cánoves
439 P. Aberrant repair and fibrosis development in skeletal muscle. *Skelet Muscle*.
440 2011;1(1):21.
- 441 16. Ceco E, McNally EM. Modifying muscular dystrophy through transforming growth
442 factor- β . *FEBS J*. 2013;280(17):4198-209.
- 443 17. Shimizu-Motohashi Y, Komaki H, Motohashi N, Takeda S, Yokota T, Aoki Y.
444 Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of
445 Therapeutic Approaches. *J Pers Med*. 2019;9(1):1.
- 446 18. Mendell JR, Rodino-Klapac L, Sahenk Z, Malik V, Kaspar BK, Walker CM, Clark KR.
447 Gene therapy for muscular dystrophy: lessons learned and path forward. *Neurosci Lett*.
448 2012;527(2):90-9.
- 449 19. Wells DJ. What is the level of dystrophin expression required for effective therapy of
450 Duchenne muscular dystrophy? *J Muscle Res Cell Motil*. 2019 ;40(2):141-150.
- 451 20. Awano H, Matsumoto M, Nagai M, Shirakawa T, Maruyama N, Iijima K, Nabeshima
452 YI, Matsuo M. Diagnostic and clinical significance of the titin fragment in urine of
453 Duchenne muscular dystrophy patients. *Clin Chim Acta*. 2018;476:111-116.
- 454 21. Garrod P, Eagle M, Jardine PE, Bushby K, Straub V. Myoglobinuria in boys with
455 Duchenne muscular dystrophy on corticosteroid therapy. *Neuromuscul Disord*. 2008
456 ;18(1):71-3.
- 457 22. Raimondo TM, Mooney DJ. Anti-inflammatory nanoparticles significantly improve
458 muscle function in a murine model of advanced muscular dystrophy. *Sci Adv*.
459 2021;7(26):eabh3693.
- 460 23. Thomas GD, Ye J, De Nardi C, Monopoli A, Ongini E, Victor RG. Treatment with a
461 nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model
462 of Duchenne muscular dystrophy. *PLoS One*. 2012;7(11):e49350.

- 463 24. Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, Jain M, Kleijnen
464 J. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy:
465 an evidence review. *Orphanet J Rare Dis.* 2017;12(1):79
- 466 25. Kieny P, Chollet S, Delalande P, Le Fort M, Magot A, Pereon Y, Perrouin Verbe B.
467 Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM
468 Yolaine de Kepper centre between 1981 and 2011. *Ann Phys Rehabil Med.*
469 2013;56(6):443-54.
- 470 26. Duan D. Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular
471 Dystrophy. *Mol Ther.* 2018;26(10):2337-2356.
- 472 27. Echevarría L, Aupy P, Goyenvallé A. Exon-skipping advances for Duchenne muscular
473 dystrophy. *Hum Mol Genet.* 2018;27(R2):R163-R172.
- 474 28. Dzierlega K, Yokota T. Optimization of antisense-mediated exon skipping for
475 Duchenne muscular dystrophy. *Gene Ther.* 2020;27(9):407-416. doi: 10.1038/s41434-
476 020-0156-6.
- 477 29. Olson EN. Toward the correction of muscular dystrophy by gene editing. *Proc Natl*
478 *Acad Sci U S A.* 2021;118(22):e2004840117.
- 479 30. Kourakis S, Timpani CA, Campelj DG, Hafner P, Gueven N, Fischer D, Rybalka E.
480 Standard of care versus new-wave corticosteroids in the treatment of Duchenne
481 muscular dystrophy: Can we do better? *Orphanet J Rare Dis.* 2021;16(1):117. doi:
482 10.1186/s13023-021-01758-9.
- 483 31. Boziki MK, Kesidou E, Theotokis P, Mentis AA, Karafoulidou E, Melnikov M,
484 Sviridova A, Rogovski V, Boyko A, Grigoriadis N. Microbiome in Multiple Sclerosis;
485 Where Are We, What We Know and Do Not Know. *Brain Sci.* 2020;10(4):234.
- 486 32. Raghavan K, Dedeepiya VD, Yamamoto N, Ikewaki N, Sonoda T, Kurosawa G,
487 Iwasaki M, Kandaswamy R, Senthilkumar R, Preethy S, Abraham SJK. Beneficial

488 reconstitution of gut microbiota and control of alpha-synuclein and curli-amyloids-
489 producing enterobacteria, by beta 1,3-1,6 glucans in a clinical pilot study of autism and
490 potentials in neurodegenerative diseases. medRxiv 2021.10.26.21265505; doi:
491 10.1101/2021.10.26.21265505

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509 **Tables and Figures**

510 Table 1: Demographics and baseline characteristics

	Subject	Age in years	Weight in kgs	Exon Deletion	Ambulatory/ Non-Ambulatory
Control Steroid -ve	1	7	12	10 & 11	Ambulatory
	2	10	27	46-55	Non-Ambulatory
	3	19	48		Ambulatory
	4	14	60	8 to 48	Non-Ambulatory
	5	15	55	10-11/Dup	Non-Ambulatory
Control Steroid +ve	1	19	65	44	Non-Ambulatory
	2	7	25	5 & 6	Ambulatory
	3	7	21	49-52	Ambulatory
	4	13	48	52	Ambulatory
N-163 Steroid -ve	1	10	28	48-50	Ambulatory
	2	4	10	45-50	Ambulatory
	3	13	38	45-50	Ambulatory
	4	10	45	60	Ambulatory
	5	7	39	10-11/ Dup	Non-Ambulatory
	6	8	21	49-52	Ambulatory
	7	13	39	43	Non-Ambulatory
	8	14	40		Non-Ambulatory
	9	7	22	44-57/Dup	Ambulatory
N-163 Steroid +ve	1	5	18	48-50	Non-Ambulatory
	2	14	59	17	Ambulatory
	3	15	40	60	Ambulatory
	4	10	20	48-52	Ambulatory
	5	10	36	48-50	Ambulatory
	6	14	58	18-29	Non-Ambulatory
	7	10	22	48-52	Ambulatory
	8	12	36	48-52	Non-Ambulatory
	9	15	29	07-Jun	Ambulatory

511

512

513


514

515 Table 2: Medical research council (MRC) grading of muscle power in the study groups

Subject	Ambulatory/Non-ambulatory	Baseline	Post-intervention	Progression
Control group				
1	Ambulatory	151	165	Improved
2	Ambulatory	133	162	Improved
3	Non-ambulatory	70	80	Improved
4	Non-ambulatory	164	164	No change
5	Non-ambulatory	109	106	Worsened
6	Non-ambulatory	102	105	Improved
7	Non-ambulatory	117	115	Worsened
8	Non-ambulatory	110	109	No change
9	Non-ambulatory	105	102	Worsened
Treatment Group				
1	Ambulatory	134	133	Worsened
2	Ambulatory	146	163	Improved
3	Ambulatory	119	131	Improved
4	Ambulatory	127	136	Improved
5	Ambulatory	154	160	Improved
6	Ambulatory	158	168	Improved
7	Non-ambulatory	102	119	Improved
8	Non-ambulatory	116	117	Improved
9	Non-ambulatory	127	127	No change
10	Non-ambulatory	120	131	Improved
11	Non-ambulatory	96	107	Improved
12	Non-ambulatory	111	122	Improved
13	Non-ambulatory	117	113	Worsened
14	Non-ambulatory	108	108	No change
15	Non-ambulatory	103	107	Improved
16	Non-ambulatory	145	148	Improved
17	Non-ambulatory	93	119	Improved
18	Non-ambulatory	Test couldn't be performed		


516

517



518


519 Figure 1: CONSORT flow diagram of the trial



520

521 Figure 2: IL-6 showed the most significant decrease in the N-163 Steroid -ve group compared

522 to other groups. (*p-value significance < 0.05)




523

524 Figure 3: Levels of IL-13 levels showed statistically significant increase in control groups

525 and decrease in treatment groups (*p-value significance < 0.05)


526



527


528 Figure 4: Levels of TGF-β showed significant decrease in the N-163 Steroid -ve group

529 compared to other groups (*p-value significance < 0.05)




530

531 Figure 5: Levels of dystrophin showed significant increase in the N-163 Steroid -ve group
532 compared to other groups (*p-value significance < 0.05)



533

534 Figure 6: Levels of A. haptoglobin; B. CK and C. urine myoglobin in various groups of the
 535 study (*p-value significance < 0.05)



536

537 Figure 7: Levels of A. titin, B. TNF- α and C. cystatin C in various groups of the study (*p-
538 value significance < 0.05)


539

540

541

542

543



544

545 Figure 8: 6MWT and NSAA results in various groups of the study (*p-value significance <
546 0.05)